Monoclonal antibodies constitute a promising class of targeted anticancer agents that
enhance natural immune system functions to suppress cancer cell activity and eliminate …

Unprecedented advances have been made in cancer treatment with the use of immune
checkpoint blockade (ICB). However, responses are limited to a subset of patients, and …

Bispecific antibodies (bsAbs) enable novel mechanisms of action and/or therapeutic
applications that cannot be achieved using conventional IgG-based antibodies …

The clinical development of 4–1BB agonists for cancer immunotherapy has raised
substantial interest during the past decade. The first generation of 4–1BB agonistic …

In the tumor microenvironment, T cells, B cells, and many other cells play important and
distinct roles in anti‐tumor immunotherapy. Although the immune checkpoint blockade and …

Hepatocellular carcinoma (HCC) is one of the most lethal tumors in China and worldwide,
although first-line therapies for HCC, such as atezolizumab and bevacizumab, have been …

Agonist antibodies that target immune checkpoints, such as those in the tumor necrosis
factor receptor (TNFR) superfamily, are an important class of emerging therapeutics due to …

Recent progressions in immunotherapy have transformed cancer treatment, providing a
promising strategy that activates the immune system of the patient to find and eliminate …

Background Ivuxolimab (PF-04518600) and utomilumab (PF-05082566) are humanized
agonistic IgG2 monoclonal antibodies against OX40 and 4-1BB, respectively. This first-in …

In recent years, the development of bispecific antibodies (bsAbs) has been rapid, with many
new structures and target combinations being created. The boom in bsAbs has led to the …